CORONA

CORONA Remedies Limited

Formulations across women's healthcare, cardio-diabetes, pain management and urology segments

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

coronaremedies.com

Ask AI

Key metrics

Price as of 2026-10-16

Stock price

₹2003.90

Market cap

12,254 Cr

Stock P/E

61.6

P/B

16.41

Dividend yield

0.4%

ROE (FY26)

24.8%

ROCE (FY26)

27.8%

Operating margin (FY26)

18.2%

Debt / equity (FY26)

0.19

OCF / EBITDA (FY26)

78.2%

OCF / EBITDA (3Y)

83.8%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

CORONA (CORONA Remedies) develops, makes and sells branded prescription medicines in India, mainly to specialist and super-specialist doctors, across women's healthcare, cardio-metabolic, pain management and urology.

Company snapshot

41stBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Positives

✓Debt-to-equity of 0.19x — the company is largely funded by its own money, not borrowed funds.

2 more signals from the filings.Sign in free to see them all

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

Metric	Sept 2025	Dec 2025	Mar 2026	Jun 2026
Sales	361 Cr	342 Cr	353 Cr	422 Cr
Operating expenses (approx.)	283 Cr	259 Cr	291 Cr	329 Cr
EBITDA	78 Cr	83 Cr	62 Cr	93 Cr
OPM %	21.7%	24.3%	17.6%	22.0%
Other income	2 Cr	2 Cr	4 Cr	3 Cr
Interest	2 Cr	2 Cr	1 Cr	3 Cr
Depreciation	9 Cr	9 Cr	10 Cr	13 Cr
Profit before tax	70 Cr	55 Cr	55 Cr	80 Cr
Tax %	25.0%	25.2%	17.2%	25.2%
Net profit	52 Cr	41 Cr	45 Cr	60 Cr
EPS (₹)	₹8.55	₹6.75	₹7.41	₹9.83

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	884 Cr	1,014 Cr	1,196 Cr	1,403 Cr	Sign in free for the trailing twelve months
Operating expenses (approx.)	756 Cr	860 Cr	956 Cr	1,110 Cr	Sign in free for the trailing twelve months
EBITDA	128 Cr	155 Cr	240 Cr	293 Cr	Sign in free for the trailing twelve months
OPM %	14.5%	15.3%	20.1%	20.9%	Sign in free for the trailing twelve months
Other income	7 Cr	6 Cr	6 Cr	11 Cr	Sign in free for the trailing twelve months
Interest	4 Cr	14 Cr	11 Cr	7 Cr	Sign in free for the trailing twelve months
Depreciation	20 Cr	28 Cr	37 Cr	38 Cr	Sign in free for the trailing twelve months
Profit before tax	111 Cr	118 Cr	199 Cr	240 Cr	Sign in free for the trailing twelve months
Tax %	23.4%	23.6%	24.7%	23.0%	Sign in free for the trailing twelve months
Net profit	85 Cr	91 Cr	149 Cr	185 Cr	Sign in free for the trailing twelve months
EPS (₹)	₹14.57	₹14.80	₹24.43	₹30.27	Sign in free for the trailing twelve months
Dividend payout %	—	—	—	0.0%	Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	61 Cr	61 Cr	61 Cr	61 Cr
Reserves	347 Cr	419 Cr	545 Cr	686 Cr
Borrowings	2 Cr	134 Cr	63 Cr	143 Cr
Other liabilities	184 Cr	216 Cr	261 Cr	315 Cr
Total liabilities	595 Cr	831 Cr	930 Cr	1,205 Cr
Fixed assets (net)	184 Cr	191 Cr	199 Cr	291 Cr
CWIP	65 Cr	121 Cr	186 Cr	143 Cr
Investments	31 Cr	26 Cr	26 Cr	26 Cr
Loans & advances	—	—	—	0.26 Cr
Inventories	105 Cr	98 Cr	129 Cr	125 Cr
Trade receivables	87 Cr	100 Cr	118 Cr	146 Cr
Cash & bank	14 Cr	3 Cr	3 Cr	2 Cr
Other assets	108 Cr	292 Cr	268 Cr	472 Cr
Total assets	595 Cr	831 Cr	930 Cr	1,205 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operating activity	103 Cr	157 Cr	190 Cr	229 Cr
Cash from investing	-50 Cr	-267 Cr	-84 Cr	-256 Cr
Cash from financing	-45 Cr	99 Cr	-107 Cr	25 Cr
Net cash flow	8 Cr	-11 Cr	0.07 Cr	-1 Cr
Free cash flow (OCF − Capex)	9 Cr	-129 Cr	99 Cr	55 Cr

Ratios

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROCE %	28.0%	21.6%	31.3%	27.8%
ROE %	20.8%	18.8%	24.6%	24.8%
Debtor days	36	36	36	38
Inventory days	387	349	461	440
Days payable	347	406	511	517
Cash conversion cycle	76	-21	-14	-40
OCF / EBITDA %	80.2%	101.3%	79.4%	78.2%
OCF / EBITDA % (3 years)	—	—	86.1%	83.8%
Debt / equity	0.0057	0.28	0.10	0.19
Current ratio	2.12	1.29	1.41	0.96
Net debt / EBITDA	-0.10	0.85	0.25	0.48